STM publisher Elsevier, Netherlands, has announced that Sanofi, one of the world's leading pharmaceutical organisations, has implemented QUOSA's literature management tools to automate adverse event monitoring. QUOSA powers the retrieval, storage, tagging and annotation of relevant case reports, allowing for the creation of a centralised repository of product-related scientific literature.
This centralised repository supports Sanofi's Pharmacovigilance team in drug safety and adverse event monitoring, ensuring patient safety and compliance with regulatory reporting requirements in all the markets in which it operates.
QUOSA provides software and services to life science companies, enabling them to centralise repositories of scientific literature related to drugs and medical devices, as well as receive alerts about new articles related to their products and other market developments. These not only help Pharmacovigilance and Medical Affairs teams carry out their work effectively and quickly, they also ensure sound information management processes and compliance with regulatory requirements.
QUOSA's pharmacovigilance solution features three elements that help companies meet their literature tracking objectives. First, Elsevier provides prompt customised professional services through its dedicated Life Sciences Integration Services team. Second, QUOSA can be used as either a desktop application or browser-based technology, facilitating secure and scalable information sharing across multiple regions. Third, QUOSA easily integrates with already existing literature resources like third-party publisher platforms, A&I databases like Embase, and document delivery vendors.
QUOSA is part of Elsevier Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow; including TargetInsights®, Pathway Studio™, Reaxys ®, Reaxys ® Medicinal Chemistry, PharmaPendium® and Embase®.
